MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-13-2025
Vaxart DSO Ratio 2011-2026 | VXRT
Annual DSO Ratio Vaxart
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 74.9 | 155 | 82.9 | 30.1 K | 134 | 158 | 24.6 | 27.5 | 187 | 99.4 | 119 | - | 24.5 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 30.1 K | 24.5 | 2.6 K |
Quarterly DSO Ratio Vaxart
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 29.6 | 6.64 | 15.9 | - | 15.5 | 11.7 | 74.4 | - | 9.84 | 9.84 | 19.2 | - | - | - | 81.6 | 161 | 67.8 | 329 | 93.2 | 85.6 | 115 | 58.3 | 62.1 | 84.3 | 727 | 3.89 K | 45.7 | 92.8 | 583 | 270 | 73.6 | 75.6 | 62.8 | 21.3 | 2.2 K | 58.8 | 639 | 130 | 6.94 K | 223 | 424 | 676 | 338 | 2.95 | 1.28 K | 181 | 4.13 K | 98.2 | 89.4 | 54.3 | 83 | 76.1 | 390 | 26.9 | 7.23 | 41.1 | 79.2 | 24.2 | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 6.94 K | 2.95 | 478 |
DSO Ratio of other stocks in the Biotechnology industry
| Issuer | DSO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Alnylam Pharmaceuticals
ALNY
|
58.1 | $ 330.79 | 3.74 % | $ 43.3 B |  USA |
 |
I-Mab
IMAB
|
271 | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
84.7 | - | - | $ 40.3 B | USA |
 |
Midatech Pharma plc
MTP
|
204 | - | -18.52 % | $ 27.3 M |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
2.75 K | - | -1.52 % | $ 24.7 M | USA |
 |
Acorda Therapeutics
ACOR
|
48.3 | - | -24.86 % | $ 820 K | USA |
 |
Adverum Biotechnologies
ADVM
|
222 | - | - | $ 86.2 M | USA |
 |
Advaxis
ADXS
|
88.1 | - | -9.65 % | $ 45.9 M | USA |
 |
Aeterna Zentaris
AEZS
|
146 | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
186 | - | -10.17 % | $ 12.2 K | USA |
 |
AIkido Pharma
AIKI
|
17.9 | - | 1.93 % | $ 17.4 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
216 | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
0.114 | - | - | $ 26.5 M | USA |
 |
Alpine Immune Sciences
ALPN
|
154 | - | - | $ 2.17 B | USA |
 |
Aquestive Therapeutics
AQST
|
103 | $ 4.11 | -0.48 % | $ 439 M | USA |
 |
Aravive
ARAV
|
16.8 | - | -13.39 % | $ 1.45 M | USA |
 |
Arcturus Therapeutics Holdings
ARCT
|
21.2 | $ 8.24 | 2.55 % | $ 226 M |  Israel |
 |
Aptinyx
APTX
|
46.9 | - | -39.0 % | $ 4.57 M | USA |
 |
CureVac N.V.
CVAC
|
13.6 | - | - | $ 867 M |  Germany |
 |
Celldex Therapeutics
CLDX
|
321 | $ 31.36 | 0.97 % | $ 2.08 B | USA |
 |
Arcutis Biotherapeutics
ARQT
|
106 | $ 23.46 | -0.72 % | $ 2.98 B | USA |
 |
Ayala Pharmaceuticals
AYLA
|
61.7 | - | - | $ 7.46 M | Israel |
 |
BeiGene, Ltd.
BGNE
|
52.6 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
bluebird bio
BLUE
|
2.47 | - | - | $ 546 M | USA |
 |
Brickell Biotech
BBI
|
254 | - | -5.38 % | $ 6.06 M | USA |
 |
Ardelyx
ARDX
|
58 | $ 6.01 | 1.18 % | $ 1.45 B | USA |
 |
CASI Pharmaceuticals
CASI
|
87.4 | - | - | $ 35.4 M | USA |
 |
ChemoCentryx
CCXI
|
3.1 | - | - | $ 3.74 B | USA |